Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2003European Journal of Gastroenterology & Hepatology

Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFα antibodies (infliximab)

View Full Paper
Ask AI
Bookmark
Share

Authors

EGEsther García-PlanellaHospital de Sant PauEDEugeni DomènechCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y DigestivasMEMaría EsteveMútua Terrassa

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

García-Planella et al. (2003) studied this question.

synapsesocial.com/papers/6a993a544dca4b63f8f5b05fhttps://doi.org/10.1097/00042737-200304000-00003
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease1997 · 3,169 citations
  2. 2Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease1999 · 2,766 citations
  3. 3Infliximab in Crohn's Disease: First Anniversary Clinical Experience2000 · 235 citations
  4. 4Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety2007 · 102 citations
  5. 5Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients2001 · 289 citations